Article
Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies.
Current neuropharmacology - 1 Jan 2021
Garcia-Rosa Sheila, de Freitas Brenha Bianca, da Rocha Vinicius Felipe, Goulart Ernesto, Silva Araujo Bruno Henrique
Abstract excerpt
Epilepsy is the most common chronic neurologic disorder in the world, affecting 1-2% of the population. Besides, 30% of epilepsy patients are drug-resistant. Genomic mutations seem to play a key role in its etiology and knowledge of strong effect mutations in protein structures might improve prediction and the development of efficacious drugs to treat epilepsy. Several genetic association studies have been...
Topics
Join the communities discussing this publication.